pentamidine has been researched along with Congenital Myotonic Dystrophy in 8 studies
Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.
pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a context of drug repurposing, pentamidine (PTM), an FDA-approved antiparasitic drug, has been proposed to reverse the splicing defects associated in myotonic dystrophy type 1 (DM1)." | 8.31 | Repurposing pentamidine using hyaluronic acid-based nanocarriers for skeletal muscle treatment in myotonic dystrophy. ( Boschi, F; Briançon, S; Calderan, L; Carras, J; Carton, F; Galiè, M; Jacquier, A; Lollo, G; Malatesta, M; Perduca, M; Repellin, M; Schaeffer, L, 2023) |
| "In a context of drug repurposing, pentamidine (PTM), an FDA-approved antiparasitic drug, has been proposed to reverse the splicing defects associated in myotonic dystrophy type 1 (DM1)." | 4.31 | Repurposing pentamidine using hyaluronic acid-based nanocarriers for skeletal muscle treatment in myotonic dystrophy. ( Boschi, F; Briançon, S; Calderan, L; Carras, J; Carton, F; Galiè, M; Jacquier, A; Lollo, G; Malatesta, M; Perduca, M; Repellin, M; Schaeffer, L, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, TL | 1 |
| Mayence, A | 1 |
| Vanden Eynde, JJ | 1 |
| Repellin, M | 1 |
| Carton, F | 1 |
| Boschi, F | 1 |
| Galiè, M | 1 |
| Perduca, M | 1 |
| Calderan, L | 1 |
| Jacquier, A | 1 |
| Carras, J | 1 |
| Schaeffer, L | 1 |
| Briançon, S | 1 |
| Lollo, G | 1 |
| Malatesta, M | 1 |
| Yenigun, VB | 1 |
| Sirito, M | 1 |
| Amcheslavky, A | 1 |
| Czernuszewicz, T | 1 |
| Colonques-Bellmunt, J | 1 |
| García-Alcover, I | 1 |
| Wojciechowska, M | 1 |
| Bolduc, C | 1 |
| Chen, Z | 1 |
| López Castel, A | 1 |
| Krahe, R | 1 |
| Bergmann, A | 1 |
| Neaga, IO | 1 |
| Hambye, S | 1 |
| Bodoki, E | 1 |
| Palmieri, C | 1 |
| Ansseau, E | 1 |
| Belayew, A | 1 |
| Oprean, R | 1 |
| Blankert, B | 1 |
| Coonrod, LA | 1 |
| Nakamori, M | 2 |
| Wang, W | 1 |
| Carrell, S | 1 |
| Hilton, CL | 1 |
| Bodner, MJ | 1 |
| Siboni, RB | 1 |
| Docter, AG | 1 |
| Haley, MM | 1 |
| Thornton, CA | 2 |
| Berglund, JA | 2 |
| Chakraborty, M | 1 |
| Selma-Soriano, E | 1 |
| Magny, E | 1 |
| Couso, JP | 1 |
| Pérez-Alonso, M | 1 |
| Charlet-Berguerand, N | 1 |
| Artero, R | 1 |
| Llamusi, B | 1 |
| Warf, MB | 1 |
| Matthys, CM | 1 |
| Cooper, TA | 1 |
1 review available for pentamidine and Congenital Myotonic Dystrophy
| Article | Year |
|---|---|
Some non-conventional biomolecular targets for diamidines. A short survey.
Topics: Amidines; Animals; Diabetes Mellitus, Type 2; DNA; Enzymes; Humans; Hypertension; Ion Channels; Myot | 2014 |
7 other studies available for pentamidine and Congenital Myotonic Dystrophy
| Article | Year |
|---|---|
Repurposing pentamidine using hyaluronic acid-based nanocarriers for skeletal muscle treatment in myotonic dystrophy.
Topics: Humans; Hyaluronic Acid; Muscle, Skeletal; Myotonic Dystrophy; Pentamidine | 2023 |
(CCUG)
Topics: Animals; Apoptosis; Disease Models, Animal; DNA Repeat Expansion; Drosophila melanogaster; Drosophil | 2017 |
Affinity capillary electrophoresis for identification of active drug candidates in myotonic dystrophy type 1.
Topics: Benzamidines; Drug Evaluation, Preclinical; Electrophoresis, Capillary; HeLa Cells; Humans; Ligands; | 2018 |
Reducing levels of toxic RNA with small molecules.
Topics: Animals; Cells, Cultured; Disease Models, Animal; Female; Male; Mice; Myotonic Dystrophy; Pentamidin | 2013 |
Pentamidine rescues contractility and rhythmicity in a Drosophila model of myotonic dystrophy heart dysfunction.
Topics: Animals; Arrhythmias, Cardiac; Diastole; Disease Models, Animal; Drosophila melanogaster; Drosophila | 2015 |
Pentamidine reverses the splicing defects associated with myotonic dystrophy.
Topics: Alternative Splicing; Animals; Disease Models, Animal; HeLa Cells; Humans; Mice; Myotonic Dystrophy; | 2009 |
Chemical reversal of the RNA gain of function in myotonic dystrophy.
Topics: Alternative Splicing; Animals; Disease Models, Animal; Humans; Mice; Myotonic Dystrophy; Pentamidine | 2009 |